carmustine - CISMeF

Preferred Label : carmustine;

MeSH definition : A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed);

MeSH synonym : n,n'-bis(2-chloroethyl)-n-nitrosourea; fivb; 1,3-bis(2-chloroethyl)-1-nitrosourea; bcnu;

MeSH hyponym : BiCNU; nitrumon;

MeSH CAS label : urea, N,N'-bis(2-chloroethyl)-N-nitroso-;

MeSH Related Number : 154-93-8 (Carmustine);

Registry Number MeSH : 154-93-8;

Wikipedia link : https://en.wikipedia.org/wiki/Carmustine;

Codes EINECS : 205-838-2;

Is substance : O;

UNII : U68WG3173Y;

InChIKey : DLGOEMSEDOSKAD-UHFFFAOYSA-N;

Details

Origin ID

D002330;

UMLS CUI

C0007257;

ATC code(s)
- carmustine [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- Carmustine poisoning (disorder) [SNOMED CT concept]
- carmustine [Substance BNPC]
Currated CISMeF NLP mapping
- Carmustine [ICD-11 Extension code]
- Carmustine [NCIt concept]
- Carmustine (substance) [SNOMED CT concept]
- carmustine [SNOMED Notion]
Pharmacological action(s)
- antineoplastic agents, alkylating [MeSH Descriptor]
Record concept(s)
- BiCNU [MeSH concept]
- carmustine [MeSH concept]
- nitrumon [MeSH concept]
Related MeSH Supplementary Concept(s)
- 1,3-bis(3-chloro-2-butyl)-1-nitrosourea [MeSH Supplementary Concept]
- 2-((((2-chloroethyl)nitrosoamino)carbonyl)amino)propanamide [MeSH Supplementary Concept]
- 2-chloroethyl-N-nitrosourea hydrochloride [MeSH Supplementary Concept]
- ABC protocol [MeSH Supplementary Concept]
- ABCM protocol [MeSH Supplementary Concept]
- BACT protocol [MeSH Supplementary Concept]
- BAEC protocol [MeSH Supplementary Concept]
- BAFMi protocol [MeSH Supplementary Concept]
- BAVC protocol [MeSH Supplementary Concept]
- BBVDD protocol [MeSH Supplementary Concept]
- BCHE protocol [MeSH Supplementary Concept]
- BCOMM protocol [MeSH Supplementary Concept]
- BCP protocol [MeSH Supplementary Concept]
- BCPP protocol [MeSH Supplementary Concept]
- BCVP protocol [MeSH Supplementary Concept]
- BEAM protocol [MeSH Supplementary Concept]
- BEAM regimen [MeSH Supplementary Concept]
- BEM protocol [MeSH Supplementary Concept]
- BFHM protocol [MeSH Supplementary Concept]
- BMP protocol [MeSH Supplementary Concept]
- BMPD protocol [MeSH Supplementary Concept]
- BMVC protocol [MeSH Supplementary Concept]
- BOMES protocol [MeSH Supplementary Concept]
- BOPP protocol [MeSH Supplementary Concept]
- BVAM protocol [MeSH Supplementary Concept]
- BVCPP protocol [MeSH Supplementary Concept]
- CBV protocol [MeSH Supplementary Concept]
- DBCT protocol [MeSH Supplementary Concept]
- DBPT protocol [MeSH Supplementary Concept]
- DBPT regimen [MeSH Supplementary Concept]
- DEMOB protocol [MeSH Supplementary Concept]
- Dexa-BEAM protocol [MeSH Supplementary Concept]
- EBAP protocol [MeSH Supplementary Concept]
- FAB protocol [MeSH Supplementary Concept]
- FBM protocol [MeSH Supplementary Concept]
- FIB-P protocol [MeSH Supplementary Concept]
- FIVB+P protocol [MeSH Supplementary Concept]
- FMB protocol [MeSH Supplementary Concept]
- ICBV regimen [MeSH Supplementary Concept]
- L-6 protocol [MeSH Supplementary Concept]
- M-2 protocol [MeSH Supplementary Concept]
- MBCF protocol [MeSH Supplementary Concept]
- MBVP protocol [MeSH Supplementary Concept]
- N-chloroethylnitrosourea asparaginamide [MeSH Supplementary Concept]
- N-nitroso-tris-chloroethylurea [MeSH Supplementary Concept]
- PECC protocol [MeSH Supplementary Concept]
- STAMP-I protocol [MeSH Supplementary Concept]
- UCH I protocol [MeSH Supplementary Concept]
- UCH II protocol [MeSH Supplementary Concept]
- VBAD protocol [MeSH Supplementary Concept]
- VBAMDex protocol [MeSH Supplementary Concept]
- VBAP protocol [MeSH Supplementary Concept]
- VDBCP protocol [MeSH Supplementary Concept]
- VP-BBML protocol [MeSH Supplementary Concept]
- carmustine with prolifeprosan 20 [MeSH Supplementary Concept]
- carmustine, poliferprosan 20 drug combination [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Carmustine [ICD-11 Extension code]
- Carmustine [NCIt concept]
- Carmustine (substance) [SNOMED CT concept]
- Product containing carmustine (medicinal product) [SNOMED CT concept]
- Product containing carmustine in prolonged-release intralesional implant (medicinal product form) [SNOMED CT concept]
- carmustine [ATC Code]
- carmustine [Substance BNPC]
- carmustine [SNOMED Notion]
Validated automatic mappings to BTNT
- carmustine [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients